EBS Profile
Emergent BioSolutions Inc., a leading player in the life sciences sector, specializes in providing comprehensive preparedness and response solutions aimed at combating accidental, deliberate, and naturally occurring public health threats (PHTs) within the United States. Established in 1998 and headquartered in Gaithersburg, Maryland, the company's extensive portfolio of products addresses a wide spectrum of PHTs, encompassing chemical, biological, radiological, nuclear, and explosives threats, as well as emerging infectious diseases, travel health concerns, and acute/emergency care.
Central to Emergent BioSolutions' offerings are several key vaccines and therapeutic treatments. These include BioThrax, an anthrax vaccine widely recognized for its efficacy, and ACAM2000, a crucial smallpox vaccine essential in biodefense strategies. The company also supplies Botulism Antitoxin Heptavalent for treating botulinum disease and Raxibacumab, used in both the treatment and prophylaxis of inhalational anthrax. Additionally, Emergent BioSolutions produces Anthrasil, addressing inhalational anthrax, and NARCAN, a nasal spray utilized for emergency treatment in opioid overdose situations.
Beyond vaccines and therapeutic interventions, Emergent BioSolutions is actively engaged in developing advanced pharmaceutical solutions. These include innovative products like Trobigard, a combination drug-device auto-injector, designed to enhance emergency medical response capabilities. The company's pipeline also features promising candidates such as AV7909, an anthrax vaccine under development, and UniFlu, a universal influenza vaccine aimed at providing broad protection against various flu strains.
Moreover, Emergent BioSolutions offers comprehensive contract development and manufacturing services. These encompass drug substance and product manufacturing, packaging solutions, and technology transfer services, along with robust process and analytical development capabilities. Through these initiatives, the company underscores its commitment to advancing public health preparedness and response capabilities worldwide.
|
